PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EDIT vs. PACB
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EDIT and PACB is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

EDIT vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%SeptemberOctoberNovemberDecember2025February
-56.07%
25.48%
EDIT
PACB

Key characteristics

Sharpe Ratio

EDIT:

-0.95

PACB:

-0.59

Sortino Ratio

EDIT:

-2.06

PACB:

-0.55

Omega Ratio

EDIT:

0.78

PACB:

0.93

Calmar Ratio

EDIT:

-0.79

PACB:

-0.73

Martin Ratio

EDIT:

-1.22

PACB:

-1.03

Ulcer Index

EDIT:

63.88%

PACB:

69.17%

Daily Std Dev

EDIT:

82.51%

PACB:

120.52%

Max Drawdown

EDIT:

-98.74%

PACB:

-97.65%

Current Drawdown

EDIT:

-98.08%

PACB:

-96.34%

Fundamentals

Market Cap

EDIT:

$143.63M

PACB:

$550.37M

EPS

EDIT:

-$2.54

PACB:

-$1.58

PEG Ratio

EDIT:

0.00

PACB:

-0.17

Total Revenue (TTM)

EDIT:

$1.71M

PACB:

$154.01M

Gross Profit (TTM)

EDIT:

-$2.72M

PACB:

$30.43M

EBITDA (TTM)

EDIT:

-$196.61M

PACB:

-$381.83M

Returns By Period

In the year-to-date period, EDIT achieves a 37.01% return, which is significantly higher than PACB's 2.19% return.


EDIT

YTD

37.01%

1M

42.62%

6M

-56.06%

1Y

-78.65%

5Y*

-42.03%

10Y*

N/A

PACB

YTD

2.19%

1M

14.02%

6M

25.50%

1Y

-67.42%

5Y*

-16.09%

10Y*

-12.21%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EDIT vs. PACB — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT
The Risk-Adjusted Performance Rank of EDIT is 66
Overall Rank
The Sharpe Ratio Rank of EDIT is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of EDIT is 22
Sortino Ratio Rank
The Omega Ratio Rank of EDIT is 44
Omega Ratio Rank
The Calmar Ratio Rank of EDIT is 55
Calmar Ratio Rank
The Martin Ratio Rank of EDIT is 1313
Martin Ratio Rank

PACB
The Risk-Adjusted Performance Rank of PACB is 1616
Overall Rank
The Sharpe Ratio Rank of PACB is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of PACB is 1818
Sortino Ratio Rank
The Omega Ratio Rank of PACB is 1919
Omega Ratio Rank
The Calmar Ratio Rank of PACB is 77
Calmar Ratio Rank
The Martin Ratio Rank of PACB is 2121
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. PACB - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EDIT, currently valued at -0.95, compared to the broader market-2.000.002.004.00-0.95-0.59
The chart of Sortino ratio for EDIT, currently valued at -2.06, compared to the broader market-6.00-4.00-2.000.002.004.006.00-2.06-0.55
The chart of Omega ratio for EDIT, currently valued at 0.78, compared to the broader market0.501.001.502.000.780.93
The chart of Calmar ratio for EDIT, currently valued at -0.79, compared to the broader market0.002.004.006.00-0.79-0.73
The chart of Martin ratio for EDIT, currently valued at -1.22, compared to the broader market0.0010.0020.0030.00-1.22-1.03
EDIT
PACB

The current EDIT Sharpe Ratio is -0.95, which is lower than the PACB Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of EDIT and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.20-1.10-1.00-0.90-0.80-0.70-0.60-0.50SeptemberOctoberNovemberDecember2025February
-0.95
-0.59
EDIT
PACB

Dividends

EDIT vs. PACB - Dividend Comparison

Neither EDIT nor PACB has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EDIT vs. PACB - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.74%, roughly equal to the maximum PACB drawdown of -97.65%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB. For additional features, visit the drawdowns tool.


-99.00%-98.00%-97.00%-96.00%-95.00%SeptemberOctoberNovemberDecember2025February
-98.08%
-96.34%
EDIT
PACB

Volatility

EDIT vs. PACB - Volatility Comparison

The current volatility for Editas Medicine, Inc. (EDIT) is 31.40%, while Pacific Biosciences of California, Inc. (PACB) has a volatility of 35.88%. This indicates that EDIT experiences smaller price fluctuations and is considered to be less risky than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%35.00%40.00%SeptemberOctoberNovemberDecember2025February
31.40%
35.88%
EDIT
PACB

Financials

EDIT vs. PACB - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab